GLSI

MKT CAP:$337M

Greenwich LifeSciences, Inc.

Market Cap

$337M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$23.67+$4.20 (+21.57%)

Apr 23, 2026

Company Details

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunoth...

CEO

Snehal S. Patel

IPO Date

Sep 25, 2020

Website

greenwichlifesciences.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$19M

EPS (Diluted)

-$1.46

Free Cash Flow

-$9M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q3 2025

Nov 14, 2025

$0EPS -$0.30

Q2 2025

Jun 30, 2025

$0EPS -$0.30

Q1 2025

May 20, 2025

$0EPS -$0.25

FY 2024

Apr 15, 2025

$0EPS -$1.21

Q4 2024

Apr 15, 2025

$0EPS -$0.61

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$0	-$903	-$2M
Q1 22	$0	-$903	-$2M
Q2 22	$0	-$903	-$773.3K
Q3 22	$0	-$903	-$2M
Q4 22	$0	-$903	-$3M
Q1 23	$0	-$903	-$2M
Q2 23	$0	-$903	-$2M
Q3 23	$0	-$903	-$3M
Q4 23	$0	-$903	-$3M
Q1 24	$0	-$903	-$3M
Q2 24	$0	-$903	-$3M
Q3 24	$0	-$903	-$3M
Q4 24	$0	-$903	-$8M
Q1 25	$0	-$903	-$3M
Q2 25	$0	-$876	-$4M
Q3 25	$0	$0	-$4M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$2M	-$2M
Q1 22	-$2M	-$2M
Q2 22	-$532.7K	-$532.7K
Q3 22	-$2M	-$2M
Q4 22	-$2M	-$2M
Q1 23	-$2M	-$2M
Q2 23	-$967.0K	-$967.0K
Q3 23	-$2M	-$2M
Q4 23	-$2M	-$2M
Q1 24	-$2M	-$2M
Q2 24	-$1M	-$1M
Q3 24	-$3M	-$3M
Q4 24	-$2M	-$2M
Q1 25	-$2M	-$2M
Q2 25	-$2M	-$2M
Q3 25	-$3M	-$3M

Capital Expenditures

Quarter	CapEx
Q4 21	$0
Q1 22	$2
Q2 22	$0
Q3 22	$0
Q4 22	$1
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$5
Q2 24	$0
Q3 24	$0
Q4 24	$4
Q1 25	$4
Q2 25	$3
Q3 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	—	+106.4%
Q1 22	—	+231.2%
Q2 22	—	+2.6%
Q3 22	—	+175.0%
Q4 22	—	+21.8%
Q1 23	—	+12.7%
Q2 23	—	+126.0%
Q3 23	—	+5.0%
Q4 23	—	-2.0%
Q1 24	—	+13.2%
Q2 24	—	+52.3%
Q3 24	—	+9.0%
Q4 24	—	+185.1%
Q1 25	—	+29.4%
Q2 25	—	+52.0%
Q3 25	—	+53.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$165.4K	—
Q1 22	$165.3K	—
Q2 22	$224.5K	—
Q3 22	$759.6K	—
Q4 22	$594.5K	—
Q1 23	$594.5K	—
Q2 23	$594.5K	—
Q3 23	$594.5K	—
Q4 23	$594.5K	—
Q1 24	$594.5K	—
Q2 24	$594.5K	—
Q3 24	$594.5K	—
Q4 24	$5M	—
Q1 25	$2M	—
Q2 25	$2M	—
Q3 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 21	$2M	$313.3K	—
Q1 22	$2M	—	$327.5K
Q2 22	$633.3K	—	$139.2K
Q3 22	$2M	—	$658.7K
Q4 22	$2M	—	$435.7K
Q1 23	$2M	—	$412.3K
Q2 23	$1M	$368.3K	—
Q3 23	$2M	$344.8K	—
Q4 23	$2M	—	$502.1K
Q1 24	$2M	$342.7K	—
Q2 24	$2M	$353.5K	—
Q3 24	$2M	$437.0K	—
Q4 24	$6M	—	$2M
Q1 25	$3M	$681.2K	—
Q2 25	$4M	$538.0K	—
Q3 25	$4M	$653.1K	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$27M	$0	$27M
Q1 22	$20M	$0	$20M
Q2 22	$17M	$0	$17M
Q3 22	$16M	$0	$16M
Q4 22	$13M	$0	$13M
Q1 23	$12M	$0	$12M
Q2 23	$11M	$0	$11M
Q3 23	$9M	$0	$9M
Q4 23	$7M	$0	$7M
Q1 24	$6M	$0	$6M
Q2 24	$7M	$0	$7M
Q3 24	$6M	$0	$6M
Q4 24	$4M	$0	$4M
Q1 25	$3M	$0	$3M
Q2 25	$3M	$0	$3M
Q3 25	$4M	$0	$4M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	13M	-0.6%	+46.7%
Q1 22	13M	+1.3%	+2.1%
Q2 22	13M	-1.1%	+0.2%
Q3 22	13M	-0.8%	-1.1%
Q4 22	13M	-1.4%	-1.9%
Q1 23	13M	+1.6%	-1.6%
Q2 23	13M	0.0%	-0.6%
Q3 23	13M	0.0%	+0.2%
Q4 23	13M	0.0%	+1.6%
Q1 24	13M	+0.1%	+0.1%
Q2 24	13M	+0.4%	+0.5%
Q3 24	13M	+1.8%	+2.3%
Q4 24	13M	+0.1%	+2.4%
Q1 25	13M	+0.1%	+2.4%
Q2 25	13M	+1.5%	+3.6%
Q3 25	14M	+2.0%	+3.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$0	3
Q1 22	$0	3
Q2 22	$0	3
Q3 22	$0	3
Q4 22	$0	3
Q1 23	$0	3
Q2 23	$0	3
Q3 23	$0	3
Q4 23	$0	3
Q1 24	$0	3
Q2 24	$0	3
Q3 24	$0	3
Q4 24	$0	4
Q1 25	$0	4
Q2 25	$0	4
Q3 25	$0	4

Revenue / Employee